Targeting Exciting Inflammasome Field, NodThera Raises $55m
Among Pioneers Of NLRP3 Inhibitors
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.